Compare Eli Lilly And Co (LLY) vs Royal Bank of Canada (RY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Royal Bank of Canada — how do they compare? Eli Lilly And Co trades at $1,177.57 (market cap $1.04T), while Royal Bank of Canada trades at $191.98 (market cap $262.99B). The key difference: Eli Lilly And Co is far larger — about 4× Royal Bank of Canada's market cap, and Royal Bank of Canada pays the higher dividend (2.66%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Royal Bank of Canada for 47 Days on average.
| LLY | RY | |
|---|---|---|
Market Cap | $1.04T | $262.99B |
Volume | 3,064,878 | 1,016,377 |
Sector | Health | Financials |
52-Week High | $1.28K | $217.87 |
52-Week Low | $799.57 | $143.64 |
Typical Hold Time | 93 Days | 47 Days |
Enterprise Value | $1.09T | $730.11B |
Dividend Yield | 0.59% | 2.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,179.27, down 0.79% on the day, with a bullish technical outlook and strong fundamental momentum. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 expectation. Revenue surged to $65.18 billion in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing its market leadership.
The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include competitive pressures in the obesity drug market and execution challenges in scaling production. With a consensus price target of $1,350, representing ~14% upside, the stock offers growth potential but requires monitoring of pipeline progress and market dynamics.
Royal Bank of Canada (RY) trades at $191.91, up 0.36% with a bearish technical signal despite strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $3.07 exceeding expectations, while revenue grew to $66.53B in 2025. Analyst sentiment is mixed with 43% buy ratings, though technical indicators show oversold conditions with RSI at 18.28.
RY presents a value opportunity with reasonable P/E of 17.08 and strong ROE of 17.2%, but faces technical headwinds and stretched valuations in the banking sector. The stock's 32% net margin and dividend yield around 3.7% support income investors, while near-term resistance at $192 may limit upside without fundamental catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Royal Bank of Canada
Royal Bank of Canada is one of the two largest banks in Canada. It is a diversified financial services company, offering personal and commercial banking, wealth-management services, insurance, corporate banking, and capital markets services. The bank is concentrated in Canada, with additional operations in the U.S. and other countries.
Read more on RY →
